The objective of this study was to assess the recommended DVH parameter (e.g., D2 cc) addition method used for combining EBRT and HDR plans, against a reference dataset generated from an EQD2-based DVH addition method. A revised DVH parameter addition method using EBRT DVH parameters derived from each patient's plan was proposed and also compared with the reference dataset. Thirtyone biopsy-proven cervical cancer patients who received EBRT and HDR brachytherapy were retrospectively analyzed. A parametrial and/or paraaortic EBRT boost were clinically performed on 13 patients. Ten IMRT and 21 3DCRT plans were determined. Two different HDR techniques for each HDR plan were analyzed.
| INTRODUCTION
Integration of concomitant chemotherapy, external beam radiotherapy (EBRT), and intracavitary brachytherapy (BT) is the standard of care in the curative management of locally advanced cervical cancer. 1 Using a BT boost is linked with improved pelvic control 2 and overall survival. 2, 3 The first use of BT for the treatment of cervical cancer dates back to 1903. 4 The use of three-dimensional (3D) imaging techniques, such as computerized tomography (CT) and magnetic resonance imaging (MRI), have been rapidly replacing planar x-ray imaging in BT treatment planning. This follows the recommendations of the Groupe Europ een de Curieth erapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO), [5] [6] [7] the American Brachytherapy Society (ABS), 8, 9 EMBRACE (An intErnational study on MRI-guided BRachytherapy in locally Advanced CErvical cancer)
protocol, 10 and a recent International Commission on Radiation Units and Measurements (ICRU) Report #89. 11 Volumetric dose parameters for targets and organs-at-risk (OARs) were introduced and used, allowing clinicians to customize isodose lines with the goal of achieving maximal coverage of the high-risk clinical target volume (HR-CTV) while irradiating OARs as little as possible. These adaptive, conformal BT approaches have resulted in significantly improved clinical outcomes. 12 Volumetric OAR dose constraints, such as the minimal dose of the 2 cc of normal tissue with the highest dose (D2cc) or D0.1 cc, have been investigated [13] [14] [15] as an alternative to conventional rectum and bladder point doses. These alternatives originated from the ICRU Report #38, 16 and are mainly applicable to Point A-based BT planning techniques. In order to integrate overall volumetric OAR doses (D2 cc and D0.1 cc) from EBRT and BT, it was recommended that the EBRT and BT doses be added even though the location of given hot-spots (D2 cc or D0.1 cc regions)
may not be identical for each of the plans. This was initially called a "worst case assumption" in the GEC-ESTRO recommendation, 7 but a worse case would occur due to intra-fraction organ or applicator motion. The adopted EMBRACE protocol phrase for this is "DVH parameter addition". 10 In this DVH parameter addition technique, the EBRT component dose distributions (at least for the volumetric OAR parameters (D2 cc and D0.1 cc)), are assumed to be completely uniform EBRT prescription doses following the recommendations of the EMBRACE protocol. 5, 7, 10 There have been efforts to accurately estimate overall doses from EBRT and HDR BT plans 17, 18, 19 but he previous studies were performed using either a phantom study 17 or a dosimetric planning study with no statistical analysis for six or fewer patients, 18 ,19 and they did not present a practical approach on how to estimate the overall OAR doses (e.g., D2 cc EQD2 ) without exporting and processing dose DICOM files (dose distribution (DVH EQD2 ) addition) or using DIR-based DVH analysis. In this study, we present a practical revised DVH parameter addition method where the volumetric OAR parameters (e.g., D2 cc) are simply obtained from each patient's EBRT plan, instead of assuming a completely uniform EBRT prescription dose.
The proposed, revised DVH parameter addition method was compared with the current DVH parameter addition method that has been used in the overall dose integration framework of GEC-ESTRO Siemens Medical System Inc., Erlangen, Germany). A staff physician contoured the bladder, rectum, and sigmoid structures using T2-weighted MR images. 11 A T&O applicator was reconstructed (digitized) on T1-weighted MR images. 6 The details of the HDR workflow, imaging, and planning have been previously described. [21] [22] [23] [24] An adaptive/conformal volume optimization HDR plan was retrospectively created for each clinical Point A plan through a hybrid-inverse optimization process that includes a combination of an inverse optimization and manual forward planning. The hybridinverse optimization process 21 5, 7 and the ICRU Report #89. 11 The a/ b ratio of 3 and repair halftime ðT 1=2 Þ of 1.5 hr were used.
Here N, d, and g represent a fraction number, a dose per fraction, and an incomplete repair function that is 1 for HDR. Afterward, the DVH parameters (e.g., D2 cc) in EQD2 were added for each EBRT and HDR plan. Both approaches can be simply done using an Excel spreadsheet (Microsoft Corporation, Redmond, WA, USA) available as a template on the American Brachytherapy Society website (www.americanbrachytherapy.org).
2.C | Integrated, single EQD2-based DVH as a reference dataset
In order to test these two different approaches, an integrated single EQD2-based, differential DVH was generated as a reference dataset.
This was done through three steps: (a) each physical dose map (i.e., dose DICOM file) was converted into an EQD2 dose map to account for the different fractionation schemes between the EBRT and HDR BT plans, (b) a differential DVH was generated from each EQD2 dose map that is EQD2-based, differential DVH (DVH EQD2 ), and (c) all differential DVH EQD2 were combined to create a single, integrated differential DVH EQD2 . The radiobiological plan evaluation tool, RadioBioEval, was developed in-house as a stand-alone software application in order to convert physical dose maps in DICOM format from EBRT treatment planning system (TPS) (Pinnacle, Philips Healthcare, Inc.,) and HDR TPS (BrachyVision, Varian Medical System, Inc.) into EQD2 dose maps, to generate a single, differential DVH EQD2 from EQD2 dose maps of EBRT and HDR plans and to evaluate an overall D2 cc EQD2 , D0.1 cc EQD2 , and gEUD EQD2 (see Fig. 2 ). A user put radiobiological parameters into "RadioBiological Parameters" of the RadioBioEval software to generate generalized EUD (gEUD) or other radiobiological metrics evaluated in the previous studies such as equivalent uniform dose (EUD) and tumor control probability (TCP) 27 for tumor and normal tissue complication probability (NTCP). 28 Afterward, DICOM dose files are imported through "Open Files" (seen in the left upper corner of the software, Otherwise, an a/b ratio of 3 is used. In this study, the a/b ratio of 3 was used for all OARs. In this demonstration case, a composite EBRT 
2.D | EQD2-based, generalized EUD (gEUD EQD2 ) as an additional plan evaluation metric
Currently, the GEC-ESTRO working group, 5,7 EMBRACE protocol, 10 and the ICRU report #89 11 all recommend assuming maximal dosevolume parameters. D2cc values sufficiently represent each OAR's dose distribution including whole DVH. As an additional plan evaluation metric, the use of an EQD2-based, generalized equivalent uniform dose (gEUD EQD2 ) was proposed. The gEUD EQD2 was obtained from the integrated, differential DVH EQD2 that was described in the previous section. The gEUD EQD2 is determined by solving the following eq. (2):
where n is a volume effect parameter, and EQD2 i is the differential dose bin obtained from a single integrated, differential DVH EQD2 .
The n values of the rectum, bladder, and sigmoid were 0. 
2.E | Statistical correlation analysis
The percent differences of the two different DVH parameter addition techniques were statistically analyzed in comparison with the reference dataset. The statistical differences between the two were also measured. The impact of EBRT techniques such as 3D
In-house radiobiological evaluation tool (RadioBioEval) for integrated EBRT and each HDR brachytherapy plans through which physical EBRT and HDR DICOM dose map plans (solid lines on DVH Graph) are converted into EQD2-dose maps and DVHs (dashed lines). In this demonstration case, a composite EBRT plan with EBRT boost and three HDR plans of fraction #1-#3 were imported.
conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) were examined for the EBRT cases without PA or PM boosts. The consequence of PM boost contributions were evaluated by comparing a DVH parameter addition with no PM boost assumption method and the revised DVH parameter addition method. All analysis was separately performed for Point A and conformal volume optimization HDR plans, along with separate statistical analysis on each rectum, bladder, and sigmoid. All P values were calculated based upon paired, two-sample Student t-tests.
| RESULTS AND DISCUSSION
The overall D2cc EQD2 parameters for the rectum, bladder, and sigmoid that were obtained from a revised DVH parameter addition technique presented no statistical differences (P > 0.0981) with the reference dataset values regardless of conformal, volume optimization, and Point A HDR plans (see Table 1 ). The overall D0.1cc EQD2 parameters for the rectum and sigmoid also did not present statistically significant differences between the revised DVH parameter addition and the reference dataset (P > 0.3831). Only the overall D0.1cc EQD2 values of the bladder were found to be significantly higher (P < 0.001) in the revised DVH parameter addition for either Point A or conformal HDR plan with a 5.9%-7.2% (7. Gy EQD2 ), respectively (see Table 2 ). cases for both conformal and Point A HDR plans, regardless of the rectum, bladder, or sigmoid (P > 0.3148) (see Table 3 ). For all PM boost cases, the current DVH parameter addition method assumes no contributions from 4 cm central block PM boosts. When directly compared to the revised DVH parameter addition method using values obtained from each patient's EBRT plan, D2 cc EQD2 and D0.1cc EQD2 values for all rectum, bladder, and sigmoid, regardless of conformal or Point A HDR planning technique, were statistically significantly underestimated (P < 0.008) ( Table 4) . On average, À8 to À10% (À5.4 to À8.0 Gy EQD2 ) underestimation occurred overall for OAR doses for the conformal HDR plans.
The gEUD EQD2 values were statistically different from the current evaluation dose-volume parameters of D2 cc EQD2 values for all rectum, bladder, and sigmoid, regardless of which HDR planning technique was used (conformal or Point A HDR plans (P < 0.0001)) (see Table 5 ). All D2cc EQD2 values for the conformal HDR plan cases were measured as statistically significantly lower than those of Point A HDR plan cases (P < 0.02). For the rectum and sigmoid, the conformal HDR cases presented statistically significantly lower values than the Point A cases (P < 0.0496) but not for the bladder (P = 0.06423). The absolute D2cc EQD2 values were significantly higher than gEUD EQD2 values (P < 0.0001), since D2cc EQD2 values are maximal doses while gEUD EQD2 values are radiobiological mean doses accounting for the volume effect characteristics of each organ.
In this study, we found that the overall D2cc EQD2 values for all rectum, bladder, and sigmoid for either conformal, volume optimization or Point A HDR plan that were generated through the current DVH parameter addition method, were significantly underestimated, when compared to the values obtained from the reference technique (P < 0.01) and the proposed, revised DVH parameter method HR-CTV with an EBRT PM (PA) boost for HDR was underestimated by 9.9 AE 6.2% (2.8 AE 1.4%) when a current DVH parameter addition method was used. 19 They concluded that a "dose distribution (i.e., DVH) addition" method should be considered when an EBRT boost is given. Tamaki et al. highlighted the dosimetric impact of PM boosts with 3-4 cm central block 17 through a simulated phantom setup. They found the contributions from central block of PM boost plan were on average 9% (5%-6%) and 28%-32% (11%-16%), for the D2cc EQD2 values of the rectum and bladder, respectively, when a 3 cm (4 cm) central block was used. 17 Fenkell et al. 18 also reported that an EBRT PM boost caused D2 cc EQD2 dose to increase by more than 50% over the boost prescription dose in four out of six patients and that the central PM boost shield does not predictably protect only 2% of the subjects, and they concluded that the recommended T A B L E 2 The differences of DVH parameters (i.e., D2 cc and D0.1 cc) when current DVH parameter addition and the proposed, revised DVH parameter addition were directly compared (i.e., current DVH parameter addition -the revised addition). Using DIR techniques is challenging mainly due to three factors: (a) T A B L E 4 The differences of DVH parameters (i.e., D2cc and D0.1cc) only for PM boost cases between a DVH parameter addition with the assumption of no contributions from PM boost and a revised DVH parameter addition in which D2cc and D0.1cc parameters were obtained from each patient's EBRT plan (i.e., the revised DVH parameter addition -the current DVH parameter addition). The rectum, bladder, and sigmoid D2cc EQD2 and D0.1cc EQD2 values of the current DVH parameter addition were statistically significantly underestimated when compared to the revised DVH parameter addition (p < 0.0008) regardless of HDR planning techniques; for both conformal volumeoptimization and Point A plans. ICRU report #89 11 addresses the assumption of a completely uniform EBRT dose that may not be valid for IMRT or volumetricmodulated arc therapy (VMAT), and it identifies that fact that a special analysis is required when an EBRT PA or PM boost is used.
When an EBRT PM boost is used, the evaluation of overall doses is especially challenging, 11 since the central shield PM boosts do not predictably protect the OARs (D2cc EQD2 ). However, ICRU report #89 could not present a practical DVH parameter addition approach without processing the dose DICOM files for each EBRT and HDR plan.
One way to eliminate the complexity of dose integration of EBRT and BT is using EBRT boosts as an alternative to BT boost.
Pioneering studies have investigated the feasibility of using IMRT or intensity-modulated proton therapy (IMPT) boosts. 36 15 In this study, all physical HDR plan doses (D2cc and D0.1 cc) were calculated based upon the AAPM TG 43 formula [49] [50] [51] without heterogeneity-corrections. The uncertainties of TG 43 dose calculations have been validated through a model-based dose calculation algorithm that accounts for tissue and applicator heterogeneity. 52 The uncertainties of OAR D2 cc in HDR BT plans for cervical cancer have been reported as on average 1%~3% for plastic tandemand-ring (T&R) applicators calculated using a Grid-Based Boltzmann Solver (GBBS) algorithm (Acuros, Varian Medical System, Inc.) 53 or by a collapsed-cone convolution algorithm (ACE, Elekta Ltd., Stockholm, Sweden). 54 This is also true of titanium T&O applicators. 26 
| CONCLUSION S
The overall D2 cc EQD2 values for all rectum, bladder, and sigmoid for conformal, volume optimization HDR plans generated using the current DVH parameter addition method, (which assumes a completely uniform prescription dose of EBRT), were significantly underestimated by on average À4.7%~À8.3%, when compared to the reference technique of dose distribution (DVH) addition values (P < 0.01). The revised DVH parameter addition method where the EBRT DVH parameters (e.g., D2 cc) were simply obtained from each patient's EBRT plan did not present statistical differences with the reference technique's values (P > 0.099). When PM boosts were used, there was an average À8%~À10% underestimation of overall OAR doses occurred for conformal HDR plans when using the current DVH parameter addition technique when compared to the revised DVH parameter addition. No significant differences between 3DCRT and IMRT techniques were found when using different approaches to estimate the overall OAR DVH parameters.
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